Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Her-2/neu overexpression due to polysomy 17 in breast cancer: molecular testing to guide therapeutic options.

Onkologie - 1 Jan 2011

Sahoo Rashmita, Babu V Chitti, Harini Vidya V, Patil Geeta V, Dhondalay Gopal Krishna, Kulkarni Jayashree, Nargund Ashwini R, Rao Smitha, Venkataswamy Eswarachary, Ajaikumar Bhagya S, Mohan Rao Raghavendra

Abstract excerpt

BACKGROUND: Fluorescent in situ hybridization (FISH) equivocal results for Her-2/neu still pose a diagnostic dilemma in oncology practice. In this study, we evaluate if Her-2/neu mRNA expression is an alternative to FISH for detecting Her-2/neu positivity. PATIENTS AND METHODS: Archival paraffin blocks of 54 breast cancer patients were analyzed for Her-2/neu status using immunohistochemistry (IHC), FISH, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Chromosomes, Human, Pair 17

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, erbB-2

Share to In Situ Hybridization, Fluorescence

Share to Molecular Diagnostic Techniques

Share to Reproducibility of Results

Share to Sensitivity and Specificity

Share to Up-Regulation

Source

Identifiers

PMID: 21734421
DOI: 10.1159/000329595

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Her-2/neu overexpression due to polysomy 17 in breast cancer: molecular testing to guide therapeutic options.PMID 21734421Read ↗

Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 TestingSemantic proximity Read ↗

Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily PracticeSemantic proximity Read ↗

Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.Semantic proximity Read ↗

Real-Time RT-PCR Analysis for Evaluating the Her2/neu Status in Breast CancerSemantic proximity Read ↗

Her-2/neu Gene Amplification in Low to Moderately Expressing Breast Cancers: Possible Role of Chromosome 17/Her-2/neu PolysomySemantic proximity Read ↗

Polysomy 17 and HER-2 Amplification: True, True, and UnrelatedSemantic proximity Read ↗

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.Semantic proximity Read ↗

Effect of High Copy Number of HER2 Associated With Polysomy 17 on HER2 Protein Expression in Invasive Breast CarcinomaSemantic proximity Read ↗

Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situhybridization and immunohistochemistrySemantic proximity Read ↗

Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinomaSemantic proximity Read ↗

The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity.Semantic proximity Read ↗

Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.